Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study - Quiz - MDSpire

Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study

  • By

  • Xin Wan

  • Dechuan Liu

  • Haotian Wang

  • Wei Guo

  • Xingtong Wang

  • Yangzhi Zhao

  • Ou Bai

  • June 18, 2026

  • 0 min

Share

Original Source(s)

Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study

  • by Xin Wan, Dechuan Liu, Haotian Wang, Wei Guo, Xingtong Wang, Yangzhi Zhao, Ou Bai

  • June 18, 2026

Related Content

The regulatory roles of dysregulated lactate dehydrogenase A in anti-tumor immunity within immune cells

PIGL promotes the docetaxel resistance of prostate cancer and is regulated by E3 ubiquitin ligase HUWE1

Exploratory characterization of IgG1/IgG4 glycosylation and monocyte-derived dendritic cell responses in esophageal squamous cell carcinoma